Bionomics (BNO): Channelling expertise in CNS drugs
Bionomics (BNO) is an Australian biopharmaceutical company specialising in ion channel drug discovery for central nervous system (CNS) disorders such as anxiety, post-traumatic stress disorder (PTSD) and Alzheimer’s disease, and in oncology. In addition to developing four proprietary drug candidates, BNO offers contract and partnered drug discovery based on its proprietary technology platforms: MultiCore and ionX. The sales model includes fees-for-service, licensing income, and royalties from successful partnered products. BNO is in a growth phase, with its strategic focus on commercialising BNC210, its lead CNS drug candidate in PTSD.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.